Disclosures for "Masupirdine (SUVN-502): An Update on the Phase-3 Clinical Development Program Targeting Agitation in Patients with Dementia of Alzheimer’s Type"
-
Dr. Nirogi has nothing to disclose.
-
Author has nothing to disclose
-
Satish Jetta has received intellectual property interests from a discovery or technology relating to health care.
-
Vinod Goyal has received intellectual property interests from a discovery or technology relating to health care.
-
Mr. Palacharla has stock in Suven Life Sciences Limited. Mr. Palacharla has received intellectual property interests from a discovery or technology relating to health care.
-
Vijay Benade has nothing to disclose.
-
Anil Shinde has received intellectual property interests from a discovery or technology relating to health care.
-
Mr. Abraham has nothing to disclose.
-
Mr. Pandey has nothing to disclose.
-
Mr. S has nothing to disclose.
-
Mr. Mohammed has nothing to disclose.
-
Pradeep Jayarajan has stock in Suven Life Sciences. Pradeep Jayarajan has received intellectual property interests from a discovery or technology relating to health care.
-
Venkat Jasti has stock in Suven Life Sciences Ltd. Venkat Jasti has received intellectual property interests from a discovery or technology relating to health care.